



MEDIA RELEASE

Invictus BioPharma appoints John Darling as Company Secretary

Melbourne Australia 20 February 2019 – Invictus BioPharma Limited, the Company commercialising an innovative non-invasive direct drug and vitamin delivery platform, today announced the appointment of John Darling as Company Secretary.

Mr Darling is an internationally respected lawyer and corporate advisor who maintains an extensive business and financial network. He has held multiple non-executive and executive directorships with public and private companies.

Mr Darling is chairman of The Darling Group which has interests in medical health and wellness businesses as well as securities, investment advisory and funds management.

Mr Darling said, “I am impressed with the progress made to date by the team at Invictus BioPharma. I believe the business model and strategy are sound and present a compelling opportunity rarely seen.”

Mr Darling takes over the role from Mr Mourice Garbutt who resigned on 1 February 2019.

For more information please contact:

Dr Glenn Tong
Invictus BioPharma Ltd.
Tel: +61 (0) 412 193 350

Andrew Geddes
CityPR
Tel: +61 (0) 2 9267 4511



About Invictus BioPharma Ltd.

Invictus BioPharma Ltd. is an Australian public unlisted biotechnology company developing and commercialising novel dietary supplements and prescription medicines based on natural products (tocotrienols) which have wide therapeutic potential, including: Delayed Onset Muscle Soreness, muscle recovery, exercise endurance, Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic SteatoHepatitis (NASH), pancreatic cancer, hyperlipidaemia, hypertension and diabetes. Invictus BioPharma owns and controls patent and other intellectual property rights for novel approaches to non-invasively delivering tocotrienols directly to the target tissues. The Company has a product development program for evidence-based nutraceuticals and a clinical development program for prescription medicines. For more information see: www.invictusbiopharma.com